TY - JOUR
T1 - Morphology Matters
T2 - A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria from the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases
AU - Jesinghaus, Moritz
AU - Schmitt, Maxime
AU - Lang, Corinna
AU - Reiser, Marianne
AU - Scheiter, Alexander
AU - Konukiewitz, Björn
AU - Steiger, Katja
AU - Silva, Miguel
AU - Tschurtschenthaler, Markus
AU - Lange, Sebastian
AU - Foersch, Sebastian
AU - Becker, Karl F.
AU - Saur, Dieter
AU - Friess, Helmut
AU - Halfter, Kathrin
AU - Engel, Jutta
AU - Boxberg, Melanie
AU - Pfarr, Nicole
AU - Wilhelm, Dirk
AU - Weichert, Wilko
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - The 2019 World Health Organization (WHO) classification of colorectal carcinoma (CRC) profoundly reclassified CRC subtypes and introduces tumor budding as a second major grading criterion, while condensing conventional grade into a 2-tiered system. So far it remains largely unexplored how these parameters interact with each other and whether they truly have an independent impact on patient prognosis. We reclassified a large single-center cohort of 1004 CRCs spanning 2 decades for adjusted WHO grade (low vs. high), tumor budding (Bd1/Bd2/Bd3), and CRC subtype (adenocarcinoma not otherwise specified, micropapillary, mucinous, serrated, medullary, adenoma-like, signet-ring cell, mixed adenoneuroendocrine carcinoma/neuroendocrine carcinoma, undifferentiated) according to the criteria of the 2019 WHO classification. We investigated the interaction of these parameters, their connection to stage/microsatellite status, and their significance for patient survival in the different subgroups. Specific subtypes other than adenocarcinoma not otherwise specified represented one third of all CRCs and were unevenly distributed throughout stage and microsatellite subgroups. Subtypes, WHO grade and tumor budding profoundly impacted all survival parameters (P<0.001 for all analyses), with CRC subtypes and tumor budding - but not WHO grade - being stage-independent prognosticators for all survival comparisons. WHO grade had very limited prognostic value in CRC subtypes, while tumor budding retained its strong prognostic impact in most scenarios. Accurate delineation of CRC subtypes introduced in the 2019 WHO classification provides strong stage-independent prognostic information, arguing that they should be considered in pathology reports and in clinical trials. Of the morphology-based grading schemes included in the 2019 WHO, tumor budding outperforms WHO grade.
AB - The 2019 World Health Organization (WHO) classification of colorectal carcinoma (CRC) profoundly reclassified CRC subtypes and introduces tumor budding as a second major grading criterion, while condensing conventional grade into a 2-tiered system. So far it remains largely unexplored how these parameters interact with each other and whether they truly have an independent impact on patient prognosis. We reclassified a large single-center cohort of 1004 CRCs spanning 2 decades for adjusted WHO grade (low vs. high), tumor budding (Bd1/Bd2/Bd3), and CRC subtype (adenocarcinoma not otherwise specified, micropapillary, mucinous, serrated, medullary, adenoma-like, signet-ring cell, mixed adenoneuroendocrine carcinoma/neuroendocrine carcinoma, undifferentiated) according to the criteria of the 2019 WHO classification. We investigated the interaction of these parameters, their connection to stage/microsatellite status, and their significance for patient survival in the different subgroups. Specific subtypes other than adenocarcinoma not otherwise specified represented one third of all CRCs and were unevenly distributed throughout stage and microsatellite subgroups. Subtypes, WHO grade and tumor budding profoundly impacted all survival parameters (P<0.001 for all analyses), with CRC subtypes and tumor budding - but not WHO grade - being stage-independent prognosticators for all survival comparisons. WHO grade had very limited prognostic value in CRC subtypes, while tumor budding retained its strong prognostic impact in most scenarios. Accurate delineation of CRC subtypes introduced in the 2019 WHO classification provides strong stage-independent prognostic information, arguing that they should be considered in pathology reports and in clinical trials. Of the morphology-based grading schemes included in the 2019 WHO, tumor budding outperforms WHO grade.
KW - WHO grade
KW - colorectal carcinoma subtypes
KW - morphology
KW - prognosis
KW - tumor budding
UR - http://www.scopus.com/inward/record.url?scp=85107916142&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000001692
DO - 10.1097/PAS.0000000000001692
M3 - Article
C2 - 34105518
AN - SCOPUS:85107916142
SN - 0147-5185
VL - 45
SP - 969
EP - 978
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 7
ER -